4//SEC Filing
Sooch Mina 4
Accession 0001596771-20-000109
CIK 0001228627other
Filed
Nov 8, 7:00 PM ET
Accepted
Nov 9, 5:42 PM ET
Size
10.1 KB
Accession
0001596771-20-000109
Insider Transaction Report
Form 4
Sooch Mina
DirectorPresident and CEO
Transactions
- Award
Employee Stock Option (right to buy)
2020-11-05+178,284→ 178,284 totalExercise: $0.90Exp: 2028-10-01→ Common Stock (178,284 underlying) - Award
Common Stock
2020-11-05+788,520→ 788,520 total - Award
Employee Stock Option (right to buy)
2020-11-05+158,475→ 158,475 totalExercise: $1.21Exp: 2029-12-27→ Common Stock (158,475 underlying)
Footnotes (3)
- [F1]The reporting person acquired the shares and options to acquire shares of the common stock of Rexahn Pharmaceuticals, Inc. ("Rexahn") on November 5, 2020, in exchange for shares and options to acquire shares of the common stock of Ocuphire Pharma, Inc. ("Ocuphire"), pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 17, 2020, as amended, between Rexahn, Razor Merger Sub, Inc. and Ocuphire pursuant to which Ocuphire became a wholly-owned subsidiary of Rexahn. Per the terms of the Merger Agreement, each share of Ocuphire common stock was converted into the right to receive 1.0565 shares of Rexahn common stock. Subsequent to the merger, the name of the issuer was changed from Rexahn Pharmaceuticals, Inc. to Ocuphire Pharma, Inc.
- [F2]The option is fully vested.
- [F3]19,017 shares vested on December 31, 2019, and the remaining shares vest in equal monthly installments from January 2020 through December 2021, subject to continued service.
Documents
Issuer
Ocuphire Pharma, Inc.
CIK 0001228627
Entity typeother
Related Parties
1- filerCIK 0001674006
Filing Metadata
- Form type
- 4
- Filed
- Nov 8, 7:00 PM ET
- Accepted
- Nov 9, 5:42 PM ET
- Size
- 10.1 KB